Here's an animated map showing the spread of the XFJ variant. The first sample was detected in Cote d'Ivoire in late August. After a long pause, a second sample was detected in South Africa in Dec. Then it appeared in New York in late Feb and began spreading more widely.
🧵
Recently classified XFJ is a recombinant of LF.7 and LS.2. LF.7 is descended from FLiRT JN.1.16.1. LF.7 added several Spike mutations: T22N, S31P, K182R, R190S and K444. LS.2 was descended from JN.1.18.5.
🧵
I show them above using a log scale, so you can compare their growth rates vs the most common LP.8.1.* sub-lineage: LP.8.1.1. There are more recent samples available, but the frequency analysis becomes increasingly distorted due to low volumes and patchy coverage.
🧵
LF.7.7.2 is descended from FLiRT JN.1.16.1. LF.7 added several Spike mutations: T22N, S31P, K182R, R190S and K444. Then LF.7.7.2 added the Spike H445P mutation.
LF.7.7.2 has been most successful in Canada (especially Quebec), rising to 8% frequency. The US has grown to 3%.
🧵
Here's the latest variant picture with a global scope, to mid- March.
Growth of the LP.8.1.* variant seemed to plateau at around 34%, with the XEC.* variant declining to 30%. Recent sample sizes are smaller so this might not be representative.
#COVID19 #Global #XEC #LP_8_1
🧵
The LP.8.1.* variant shows a slowing growth advantage of 2.3% per day (16% per week) over the dominant XEC.* variant, with a crossover in early March.
🧵
Among the LP.8.1.* sub-lineages, the first child lineage LP.8.1.1 has been the most successful, with accelerating growth in recent samples.
🧵
With the LP.8.1.* variant on the way to dominance in most places, it is time to ponder which variant might drive the next wave.
The leading contenders at this point are LF.7.7.2, LF.7.9, NB.1.8.1, XEC.25.1 and XFH.
#COVID19 #LF_7_7_2 #LF_7_9 #NB_1_8_1 #XEC #XFH
🧵
I show them above using a log scale, so you can compare their growth rates vs the most common LP.8.1.* sub-lineage: LP.8.1.1.
🧵
LF.7.7.2 is descended from FLiRT JN.1.16.1. LF.7 added several Spike mutations: T22N, S31P, K182R, R190S and K444. Then LF.7.7.2 added the Spike H445P mutation.
LF.7.7.2 has been most successful in Canada, rising to 12% frequency. The US has reported growth to 4%.
🧵
Here's the latest variant picture for Europe (excluding the UK), to early March.
The XEC.* variant remains dominant, but it has declined to around 31% frequency.
The LP.8.1.* variant grew to around 23%.
#COVID19 #EUR #XEC #LP_8_1
🧵
Note the recent sample volumes are very low, so this might not be a representative picture.
🧵
For Europe (excluding the UK), the LP.8.1.* variant shows an accelerating growth advantage of 4.4% per day (31% per week) over the dominant XEC.* variant. That predicts a crossover in mid-March (the data routinely lags).
🧵